FDA reaches 100 generic approvals

Genéricos/General | Posted 12/11/2021 post-comment0 Post your comment

As of September 2021, the US Food and Drug Administration (FDA) has reached an important milestone of approving more than 100 generic drug applications with a competitive generic therapy (CGT) designation.

53 MD002445

The CGT programme was designed to encourage the development and marketing of generic drugs for products with little to no competition. Now, following the inception of FDA’s CGT programme in 2017, over 100 generic drug application approvals have been made in less than four years, among a broad range of products and therapeutic areas.

A key incentive provided by the programme is that applicants for drugs that receive a CGT designation may be eligible for a 180-day period of marketing exclusivity [1], if they are the first approved applicant for that CGT and meet certain other conditions.

This ‘100 approvals’ is a key milestone for the CGT programme which has spurred the development and market availability of safe and effective generic drugs in areas of the market that previously had little to no competition. This is a step towards providing patients with more affordable access to medicine across the US.

Despite this achievement, certain practices, such as delayed market entry [2], predatory pricing and a lack of supply chain partnerships, have reduced the impact that generic medicines could have had on the lives of patients. It has been reported that these issues have led to product supply chain disruptions, shortages, and high prices of generic drug products in recent years [3, 4]. As a result, there have been calls and a number of actions [5] to improve policy to facilitate the reach of generics. These are ongoing.

Related articles
US opinion on prescription drug affordability

FDA issues new guidance for accelerated pathway for generics

Generics companies defend against pathway for illegal pay-for-delay charges

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. US brand-name drug market exclusivity periods remain relatively unchanged over the past decade [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/generics/research/us-brand-name-drug-market-exclusivity-periods-remain-relatively-unchanged-over-the-past-decade
2. GaBI Online - Generics and Biosimilars Initiative. Lawsuits and US$450 million payout for price fixing and delayed generics entry [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/policies-legislation/lawsuits-and-us-450-million-payout-for-price-fixing-and-delayed-generics-entry
3. GaBI Online - Generics and Biosimilars Initiative. Why does the US face high-priced generics and drug shortages? [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/Generics/Research/Why-does-the-US-face-high-priced-generics-and-drug-shortages
4 GaBI Online - Generics and Biosimilars Initiative. The 700-dollar vitamin: excessive generics prices in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/generics/research/The-700-dollar-vitamin-excessive-generics-prices-in-the-US
5. GaBI Online - Generics and Biosimilars Initiative. US policy to combat high-priced generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Nov 12]. Available from: www.gabionline.net/generics/research/US-policy-to-combat-high-priced-generics

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA closes Zhejiang Huahai Pharmaceutical warning letter
Application V15a16
Genéricos/General Posted 19/11/2021
New five-year medicines agreements in Australia
24-AA011041
Genéricos/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Genéricos/General Posted 23/07/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010